Skip to main content

Table 4 Base-case results combining direct and indirect effects of adrenaline use in cardiac arrest

From: Cost-effectiveness of adrenaline for out-of-hospital cardiac arrest

Analysis

Adrenaline

Placebo

Cost-effectiveness

Probability adrenaline is cost-effective at

Mean costs

Mean QALYs

Mean costs

Mean QALYs

Incremental costs

Incremental QALYs

ICER

£15,000 per QALY

£20,000 per QALY

£30,000 per QALY

Trial-based analysis (n = 21,757)1

£78,130,649

54

£48,662,440

37

£29,468,209

17

£1,693,003

0.00

0.00

0.00

Trial-based + extrapolation (n = 21,757) 1

£115,497,429

2414

£76,885,801

1938

£38,611,628

476

£81,070

0.04

0.05

0.10

Trial-based + extrapolation + lung (n = 81)

£120,803,455

2642

£82,061,552

2138

£38,741,903

504

£76,859

0.03

0.05

0.10

Trial-based + extrapolation + liver (n = 309)

£163,048,181

5452

£116,865,746

4187

£46,182,436

1264

£36,533

0.06

0.13

0.35

Trial-based + extrapolation + kidney (n = 731)

£262,782,220

9676

£220,723,823

7398

£42,058,397

2278

£18,466

0.34

0.57

0.82

Trial-based + extrapolation + lung + liver + kidney

£315,638,999

12,942

£265,879,518

9849

£49,759,481

3093

£16,086

0.41

0.68

0.90

  1. Results are presented at the UK population level and are for the combined analysis population of patients who stand to benefit directly and indirectly from adrenaline use in cardiac arrest
  2. ICER incremental cost-effectiveness ratio
  3. 1n refers to the eligible UK-wide out-of-hospital cardiac arrest patient population per year predicted from the modelling; the transplant estimates refers to predicted numbers joining waiting list each year